I could believe that. Micro cap biotech is high risk. Micro tech bio tech with low liquidity even more so. Terms for the finance offered will reflect this. But i would have thought they would have seen that prior to the deal.
We should now have enough funds to get through to the Phase 1b trial into GBM and hopefully get approval for a fast track approval trial. The. NK trial is funded by another party, so its progression should be assured. And we have another drug all ready to hit arms, so it should be good to go as well.
CarT is an expensive treatment. It takes money to keep trials on track. We have that now. This market cap makes a very attractive entry for a mid to long term holder.
CHM Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held
